ICCC Earnings Date: Nov 12, 2026 (Estimated) — ImmuCell Corporation
NASDAQ · Healthcare · Biotechnology
Updated
When is ICCC's next earnings date?
ImmuCell Corporation (ICCC) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.05 on revenue of $5.4M.
How did ICCC do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), ImmuCell Corporation posted EPS of $0.20 versus the $0.05 estimate, a beat of 300.0%. Revenue was $7.2M against a $5.4M estimate. The stock's 1-day post-earnings move was -7.8%.
How much does ICCC stock move after earnings?
ICCC beat EPS estimates in 2 of its last 2 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About ImmuCell Corporation
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | 0.05 | 0.20 | +300.00% | $7.2M | ✅ Beat | -7.80% | -7.43% | -10.92% |
| 2026-05-14 | Q1 2026 | — | 0.21 | — | $10.4M | — | +7.99% | +21.19% | +15.38% |
| 2026-03-04 | Q4 2025 | — | -0.31 | — | $7.6M | — | -1.70% | +2.94% | -0.31% |
| 2025-11-13 | Q3 2025 | — | -0.02 | — | $5.5M | — | -10.74% | -23.97% | +1.49% |
| 2025-08-14 | Q2 2025 | — | 0.06 | — | $6.4M | — | -9.18% | -11.01% | -11.46% |
| 2025-02-25 | Q4 2024 | — | 0.06 | — | $7.8M | — | +7.45% | +1.96% | -6.27% |
| 2024-11-13 | Q3 2024 | — | -0.09 | — | $6.0M | — | +1.98% | +1.98% | +39.38% |
| 2024-08-13 | Q2 2024 | — | -0.20 | — | $5.5M | ✅ Beat | -4.26% | -2.66% | -3.46% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY21 · $5.4M total
| Segment | Share | Revenue | YoY | Q2 FY18 | Q2 FY21 | Q3 FY21 | Q4 FY21 |
|---|---|---|---|---|---|---|---|
| FirstDefenseProductLineMember | 99.3% | $5.4M | — | — | $4.5M | $5.0M | $5.4M |
| OtherAnimalHealthMember | 0.7% | $41K | — | — | $69K | $117K | $41K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.